My research interests are mainly focused on liver diseases including non-alcoholic and alcoholic fatty liver diseases, and autoimmune disorder-related liver injuries. Aiming at finding cures, I have been focused on molecular cellular signaling pathways that related to hepatocyte injury, stellate cell (major fibrotic tissue producers) activation, and inflammatory responses. We recently discovered that Shc, a gene mediates aging progress, is involved in pathogenic signaling in multiple liver diseases and could be potential therapeutic target. Our laboratory has identified a potent Shc inhibitor by screening a library of FDA approved compounds. This compound idebenone has shown significant beneficial effect in several liver diseases models. Meanwhile other small molecules targeting Shc have been generated and currently under evaluation. Other pathogenic signaling in liver metabolism disorders and alcoholic injuries and therapeutic targets are being investigated as well.